Brownell Isaac, Etzel Carol J, Yang Deborah J, Taylor Sarah H, Duvic Madeleine
Department of Dermatology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Clin Lymphoma Myeloma. 2008 Apr;8(2):100-5. doi: 10.3816/CLM.2008.n.011.
Cutaneous T-cell lymphoma (CTCL) has been associated with increased risk for second malignancies. However, the degree of risk and types of second cancers detected have been inconsistent in previous studies.
To further characterize the risk for malignancy associated with CTCL, patients treated for CTCL at M. D. Anderson Cancer Center in Houston, Texas, between November 1979 and November 1999 were assessed for the occurrence of additional cancers by analysis of institutional tumor registry data.
Of 672 patients with CTCL, 112 had > or = 1 additional cancer, 37 occurring after the diagnosis of CTCL. This represents a significant elevation in cancer prevalence and incidence, with a 1.79-fold risk (95% CI, 1.22-2.39) for developing cancer after CTCL. An excess of Hodgkin and non-Hodgkin lymphoma, acute myeloid leukemia, and vulvar cancers was seen.
These data provide evidence for an increased overall incidence of second malignancy in CTCL, particularly with respect to other lymphoproliferative malignancies. Appropriate monitoring for the early detection of second cancers might be warranted in patients with CTCL.
皮肤T细胞淋巴瘤（CTCL）与发生第二原发性恶性肿瘤的风险增加相关。然而，先前研究中检测到的风险程度和第二癌症类型并不一致。
为进一步明确与CTCL相关的恶性肿瘤风险，我们通过分析机构肿瘤登记数据，对1979年11月至1999年11月期间在得克萨斯州休斯敦的MD安德森癌症中心接受CTCL治疗的患者发生其他癌症的情况进行了评估。
在672例CTCL患者中，112例发生了≥1种其他癌症，其中37例在CTCL诊断后发生。这表明癌症患病率和发病率显著升高，CTCL诊断后发生癌症的风险为1.79倍（95%CI，1.22 - 2.39）。观察到霍奇金淋巴瘤和非霍奇金淋巴瘤、急性髓细胞白血病以及外阴癌的发病增多。
这些数据为CTCL患者第二原发性恶性肿瘤的总体发病率增加提供了证据，尤其是对于其他淋巴增殖性恶性肿瘤。对于CTCL患者，可能有必要进行适当监测以早期发现第二癌症。
